Q32 Bio halts trials amid job cuts and pivots to alopecia treatment
Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it …
Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it …
Satellos Bioscience has concluded the enrolment of subjects for all four multiple-ascending dose (MAD) cohorts for the Phase I trial …
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed …
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company …
Radiopharm Theranostics’ novel imaging small molecule, RAD 101, has detected brain metastases in all 22 patients enrolled in an observational …
Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating …
A Phase III study examining a treatment for the rare genetic disorder Niemann-Pick disease has seen 87% of its participants, …
Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) inhibitor, …
Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes …
Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation that damages its tissues …
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) …
A Phase I trial of Replicate Bioscience’s self-replicating RNA-based vaccine for rabies has elicited an immune response against a disease …
Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised …
The 43rd Annual JP Morgan Healthcare Conference took place in San Francisco, California on January 13–16, 2025. This annual conference is …
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company …